Cellectar Biosciences
CLRB
35 hedge funds and large institutions have $30M invested in Cellectar Biosciences in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 7 closing their positions.
127% more call options, than puts
Call options by funds: $184K | Put options by funds: $81K
6% more capital invested
Capital invested by funds: $28.3M → $30M (+$1.71M)
0.22% more ownership
Funds ownership: 1.08% → 1.3% (+0.22%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 37 → 35 (-2)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$2.12M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.93M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$748K |
| 4 |
ACM
Altium Capital Management
New York
|
+$473K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$358K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$375K |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$176K |
| 3 |
Barclays
London,
United Kingdom
|
-$114K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$110K |
| 5 |
Millennium Management
New York
|
-$107K |
CLRB Hedge Fund Activity: Q3 2024 in Review
35 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2024, worth a combined $30M — up 6.1% from $28.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CLRB and 5 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 9 added.
The largest buyer was Rosalind Advisors, adding an estimated $2.12M. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $375K sold.
- 35 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2024, down from 37 in Q2 2024.
- Funds reported $30M of Cellectar Biosciences stock for Q3 2024, up 6.1% quarter-over-quarter.
- 5 funds opened new Cellectar Biosciences positions in Q3 2024 and 7 closed out, a net change of -2 holders.
- The largest Cellectar Biosciences buyer in Q3 2024 was Rosalind Advisors, an estimated $2.12M added.
- The largest Cellectar Biosciences seller in Q3 2024 was Hudson Bay Capital Management, an estimated $375K sold.
Based on aggregated 13F filings for Q3 2024.